Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Clearmind Medicine Inc (NQ: CMND )

3.920 -0.140 (-3.45%)
Streaming Delayed Price Updated: 1:00 PM EST, Feb 7, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 13,181
Open 3.950
Bid (Size) 3.920 (1)
Ask (Size) 4.050 (1)
Prev. Close 4.060
Today's Range 3.811 - 4.060
52wk Range 3.000 - 6.100
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
EXCLUSIVE: Next-Generation Psychedelics, MEAI - The Road Ahead
(Part four of a four-part series) See previous parts of the series: Next-Generation Psychedelics: The Case Of MEAI And Its Potential To Treat Addiction 
Via Benzinga
Israeli Biotech Develops Ketamine Analogue To Treat Major Depression With Promising Results
Israeli-based psychedelics biotech Clearmind Medicine Inc. (NASDAQ: CMND) and partners Bar-Ilan University and Professor Gal Yadid from the Gonda Multidisciplinary Brain Research Center have obtained... 
Via Benzinga

Performance

YTD
+25.24%
+25.24%
1 Month
+9.50%
+9.50%
3 Month
-33.56%
-33.56%
6 Month
-33.56%
-33.56%
1 Year
-33.56%
-33.56%

More News

Read More
Israeli Biotech Clearmind Medicine Announces Positive Pre-Clinical Results Treating Major Depression With a Novel Ketamine-Based Compound
From Clearmind Medicine Inc.
Via Globe NewsWire
Psyched: States With Psychedelics Legalization Bills, Next-Gen Molecule For Addiction Treatment And More
Via Benzinga
Hebrew University' Yissum and Israeli Biotech Clearmind Medicine’s Psychedelic-Derived Obesity Treatment Presented by Professor Joseph Tam, D.M.D., Ph.D. at Isranalytica 2023
From Clearmind Medicine Inc.
Via Globe NewsWire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Via InvestorPlace
EXCLUSIVE: Next-Generation Psychedelics, MEAI - What And When
Via Benzinga
EXCLUSIVE: Next-Generation Psychedelics, MEAI - How And Why, An Israeli Scientist Explains
Via Benzinga
Next-Generation Psychedelics: The Case Of MEAI And Its Potential To Treat Addiction
Via Benzinga
Clearmind Teams With Yissum, University of Jerusalem On 2 Psychedelic R&D Projects
Via Benzinga
Israel-Based Clearmind Successfully Completed Two R&D Projects With The Hebrew University of Jerusalem’s Tech Transfer Company, Yissum
From Clearmind Medicine Inc.
Via Globe NewsWire
Envisioning A Cocaine-Addiction Treatment: This Next-Gen Psychedelic Shows Positive Results
Via Benzinga
Israel-Based Clearmind Announces Additional Positive Results from the Third Part of its Pre-Clinical Study for Cocaine Addiction Treatment
From Clearmind Medicine Inc.
Via Globe NewsWire
Israel-Based Clearmind Medicine Successfully Completes Production of CMND-100 Drug Candidate for Clinical Trial
From Clearmind Medicine Inc.
Via Globe NewsWire
This Original Psychedelic-Based Obesity Treatment Set To First-In-Human Trials
Via Benzinga
Israel-Based Clearmind Medicine Shows Efficacy of Psychedelic- Derived Obesity Treatment in Pre-Clinical Trial
From Clearmind Medicine Inc.
Via Globe NewsWire
Israel-Based Clearmind Medicine Inc. CEO Discusses the Potential of Psychedelics for Addiction Treatment in Audio Interview with SmallCapVoice.com
Via ACCESSWIRE
What Happened With Psychedelics In The Last Year? 11 Key News Items, The Sector's Performance & Takeaways
Via Benzinga
Clearmind Medicine Inc.’s Psychedelic-Based Therapeutics Are Revolutionary To The Pharmaceutical Sector; Treating AUD In The Crosshairs ($CMND)
Via AB Newswire
Topics Intellectual Property
Exposures Intellectual Property
Clearmind Medicine Inc. Positions To Deliver A First-To-Market Psychedelic-Based Treatment For AUD ($CMND)
Via AB Newswire
Topics Intellectual Property
Exposures Intellectual Property Product Safety
Clearmind Medicine Announces Shareholders Meeting Results
From Clearmind Medicine Inc.
Via Globe NewsWire
Israel-Based Clearmind Medicine Announces First Clinical Center to Join Its Clinical Trial for Alcohol Use Disorder
From Clearmind Medicine Inc.
Via Globe NewsWire
Clearmind Medicine Inc. Scores Milestone Patent Issuance To Expedite And Protect Psychedelic-Based Treatment For AUD ($CMND)
Via AB Newswire
Topics Intellectual Property
Exposures Intellectual Property
In a New Audio Interview, Toni Loudenbeck of Traders News Source Interviews Clearmind Medicine Inc's CEO, Dr. Adi Zuloff-Shani
Via ACCESSWIRE
Israel- Based Clearmind Medicine Granted U.S. Patent for Psychedelic-Based Alcohol Substitute
From Clearmind Medicine Inc.
Via Globe NewsWire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.